Soluble variants of type I membrane proteins, and methods of using them
AssigneeThe Wistar Institute of Anatomy and Biology
InventorsAlban J. Linnenbach, Hilary Koprowski, Dorothee Herlyn
Life of this patent
Estimating the term…
Abstract
The present invention describes novel soluble variants of type I membrane protein GA733-2 and methods of making and using them. In addition, the present invention describes a method of converting type I membrane proteins into secretory proteins which may be used for active immunotherapy against carcinomas and as reagents in the detection of GA733-2 expression on tumor cells.
Claims4
A pharmaceutically acceptable composition for treatment of cancer which comprises immunogenic GA733-2E consisting of the amino acid sequence of SEQ ID NO:
- 2, and at least one other cancer treating compound in a pharmaceutically acceptable carrier.
A pharmaceutically acceptable composition which comprises immunogenic GA733-2E consisting of the amino acid sequence of SEQ ID NO:
- 2, and an immunomodulator in a pharmaceutically acceptable carrier.
A pharmaceutically acceptable composition which comprises immunogenic GA733-2E consisting of the amino acid sequence of SEQ ID NO:
- 2, in a pharmaceutically acceptable carrier, wherein said carrier is a liposome.
Dependencies are inferred from the claim text.